NIH Invents Omega-3 Boosted Cancer Vaccines
Published Date: 6/25/2026
Notice
Summary
The National Cancer Institute has created a new way to make cancer vaccines stronger by using special omega-3 fats to boost immune cells called dendritic cells. This could help scientists and companies develop better cancer treatments that work more effectively. If you’re in biotech or medicine, now’s the time to team up or license this exciting technology and help bring improved vaccines to patients faster.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
NCI Offers Licensing for Omega‑3 DC Vaccine Tech
The National Cancer Institute is offering its compositions and methods that use omega‑3 fatty acids (DHA and EPA) or pro‑resolving lipid mediators to boost dendritic cell (DC) cancer vaccine effectiveness for licensing or co‑development. The technology is at a pre‑clinical stage (in vivo validation), has NIH reference number E-231-2023, and a PCT patent was filed on September 27, 2024 (PCT/US2024/049057). NCI is actively seeking research partners and licensees to develop these therapeutic oncology applications.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
2026-14981, Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.
Previous / Next Documents
Previous: 2026-12835, Agency Information Collection Activities; Notice and Request for Comment; Intelligent Speed Assistance (ISA) User Acceptance and Effectiveness Testing Using Simulator and/or Closed Track Methods
The National Highway Traffic Safety Administration (NHTSA) wants to study how drivers feel about and use Intelligent Speed Assistance (ISA) technology by testing it in simulators and closed tracks. They’re asking the public to share their thoughts before August 24, 2026. This helps make sure the new info collection is useful and won’t waste anyone’s time or money.
Next: 2026-12843, Government Owned Inventions Available for License: C8166-45 Cell Line
The National Cancer Institute is offering a special human T-cell line called C8166-45 for licensing. This cell line helps scientists study viruses like HTLV-1 and HIV, which can cause serious diseases. Researchers and companies can now use this tool to develop better treatments, with licensing info available starting June 2026—no patents, just pure science power ready to roll!